Search for:

February 2024

In brief

On 23 January 2024, the European Commission published a proposal to amend Regulation 2017/745 (EU) on Medical Devices and Regulation (MDR) 2017/746 (EU) on In Vitro Diagnostic Medical Devices (IVDR), which regulate notification requirements in the event of an interruption in the supply of certain types of medical devices and in vitro diagnostic medical devices, the introduction of Eudamed as a tool for the diffusion of information on devices available on the European market, as well as transitional provisions for in vitro diagnostic medical devices.


Key takeaways

In particular, the proposed amendment provides for the introduction in the MDR and in the IVDR of a new Article 10a which imposes on the manufacturer the obligation to notify the competent authorities, economic operators, and healthcare institutions of the early termination of the supply of certain medical devices and in vitro diagnostic devices when such termination has the potential to cause serious harm or even a mere risk to patients or public health.

With specific reference to the MDR, the proposal also provides for the amendment of several provisions concerning the use of Eudamed, including those in Article 34. In particular, the purpose of these amendments is to remove the concept that the use of Eudamed can only become mandatory when all its modules have been declared fully functional. Indeed, the new wording of the provisions enables a gradual implementation of individual Eudamed modules once they have been audited and declared functional.

As regards the IVDR, the proposed amendment also intervenes on Article 110 by providing for, among others, the extension until 31 December 2027 of the validity of certificates issued under Directive 98/79/EC that are still valid on the date of application of the IVDR (26 May 2022) and have not been withdrawn by a notified body and, with respect to “legacy devices” covered by a certificate or declaration of conformity issued under the above Directive before 26 May 2022, the extension of the relevant transitional periods based on the class of the device.

Author

Roberto Cursano has been a lawyer in Baker McKenzie since September 2007. He focuses on healthcare law and compliance, and assists in tender procedures, the negotiation of public contracts and litigation before administrative courts. Mr. Cursano is a former administrative officer in the Italian Ministry of Health and helps clients work closely with the Italian Public Administration. He is admitted to the bar before the Italian Supreme Court and the Council of State. As well as training and tutoring in the master’s degree program on clinical trials of pharmaceutical products at the University of Rome Sapienza, Mr. Cursano regularly publishes articles and scientific contributions. He also frequently hosts and participates in seminars and presentations on pharmaceutical and administrative law matters.

Author

Riccardo Ovidi is an Associate in Baker McKenzie Rome office.

Author

Francesca R. Baratta is an Associate in Baker McKenzie Rome office.

Write A Comment